-Reuters
Barclays Maintains Equal-Weight on Colgate-Palmolive, Lowers Price Target to $77
Barclays analyst Lauren Lieberman maintains Colgate-Palmolive (NYSE:CL) with a Equal-Weight and lowers the price target from $80 to $77.
Related Posts
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer’s-Associated Agitation
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.
Morgan Stanley Maintains Overweight on IO Biotech, Lowers Price Target to $11
Morgan Stanley analyst Matthew Harrison maintains IO Biotech (NASDAQ:IOBT) with a Overweight and lowers the price target from $15 to $11.